Anti-Drug and Anti-Idiotypic Discovery Research
100% success rate across programs to date*
Anti-drug/anti-idiotypic antibody discovery designed for success, delivering reproducible results across diverse formats and assay needs.
The critical link for research
MindWalk delivers what few can claim—a 100% success rate in anti-idiotypic antibody discovery to date.*
Our programs move with speed and rigor, combining scientific expertise with highly trackable, regulatory-facing workflows designed for IND-enabling discovery. With validated assays and reproducible data packages, MindWalk provides the precision and reliability you need as candidates move into downstream development.
* “Success” refers to the generation of anti-idiotypic antibodies meeting predefined analytical criteria across Anti-ID discovery programs. It does not refer to clinical, regulatory, or therapeutic outcomes. Results may vary.
Performance driven
High-affinity and exquisite specificity
Scalable workflows with versatile formats
Customizable solutions
35+ years of experience High client retention
Clear obstacles and reduce bottlenecks
Integrate LensAI™ insights
Fully customizable discovery built to support strong outcomes
A global leader:
Delivering anti-drug discovery and research tool innovation at scale
1,100+ programs completed
Average timeline:
B cell discovery: From immunization to delivery
<12 weeks*
*Timelines may vary depending on program complexity.
Where our research makes a broad impact
Oncology + Infectious Disease + Neurodegeneration + Metabolic Disease + Rare Disease + Inflammation + Market Kits
Anti-drug discovery across complex targets
Antibody discovery + development
Versatile Applications: anti-drug & anti-idiotypic and other research tools (Western Blot, IHC, Flow Cytometry and other applications)
Target
- Target Analysis: Experience-based Antigen Design
- Tool Generation: Custom Antigen Production, Assay Development
Discovery
- Immunization: Standard, Rapid, Custom
- Hit Generation & Candidate Selection: B cell Discovery, Hybridoma Discovery
Lead
- Lead Characterization: Target Interaction Analysis
- LensAI HYFT Prime™: Binding Affinity Optimization, Target Specificity and Selectivity
- Target- and Application-specific Screening
- Protein Production: Recombinant Protein Expression in CHO, HEK293, E.coli
Stable Production Cell Line
Functional Selection
- Epitope Mapping
- Affinity
- Specificity
- Competing/Non-competing
- Pairing Identification
- Application-relevant Screening
Species Diversity
+ Rabbit
+ Rodent
Advanced Technology
+ B cell Select®
+ Hybridoma
Format Options
- Full-length IgG
- Custom Formats
Additional discovery innovation
Veterinary medicine, diagnostics and science
Used by teams across 19 of the top 20 global pharma companies, next-generation biotechs, and leading research institutions
An extension of
your team.
#1 ranking lab*
*ROOTS 2022: Antibody Discovery Services and Platforms Market (4th Edition), 2021-2035; p.118
Talk 1:1 with the team
Connect with a team who understands Anti-Drug and Anti-ID from discovery through development
Four ways to access MindWalk
We build it
Customizable offerings in biologics discovery—from target analysis to optimized leads.
You build it
Access to state-of-the-art LensAI SaaS Platform.
The Vault
Smarter starts: a portfolio of partner-ready assets.
Partnership
We are proud to partner with the best in pharma, biotech and academia organizations. Join us in creating future of human health.